LFMD Investors Have Opportunity to Join LifeMD, Inc. Fraud Investigation with the Schall Law Firm
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. LifeMD announced its Q2 2025 financial results on August 5, 2025. The Company revealed higher customer acquisition costs had added pressure on the business, especially related to its RexMD telehealth platform. Analysts from KeyBanc Capital Markets indicated that the Company 'took its eye off the ball' in the quarter, leading to its share price to drop more than 44.8% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
AAPL Stock Price Prediction: Where Apple Could Be by 2025, 2026, and 2030
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Analysts are saying that Apple could hit $410 by 2030. Bullish on AAPL? Invest in Apple on SoFi with no commissions. If it's your first time signing up for SoFi, you'll receive up to $1,000 in stock when you first fund your account. Plus, get a 1% bonus if you transfer your investments and keep them there until December 31, 2025. Apple Inc (NASDAQ:AAPL) remains one of the world's most influential and closely tracked tech stocks. Its massive installed base, iconic products, and fast-growing Services business make it a focal point for both growth and value investors. As of August 2025, Apple's share price is hovering near all-time highs as investors weigh the company's future earnings power in artificial intelligence (AI), wearables, and digital services. Below, we'll take a close look at how Apple stock is performing today, where its valuation stands, and what experts think could happen to its price in 2025, 2026, and 2030. You'll find projections from Wall Street analysts and independent models, along with an overview of the key trends, possible risks, and different opinions shaping Apple's future. Current Apple Stock Overview Market Cap: $3.25 trillion Trailing P/E Ratio: 32.36 Forward P/E Ratio: 26.95 1-Year Return: +1.86% 2025 Year to Date: Down roughly 15%, but rebounding strongly from earlier lows As of August 2025, Apple (AAPL) trades near $224 per share, recovering from a steep first-half drop of over 15% as investor sentiment improves. The stock's trailing P/E ratio of 32.36 sits well above its long-term average in the low-to-mid 20s, reflecting the market's continued premium on Apple's brand and earnings power. Over the past year, shares have inched up about 1.9%, showcasing the company's historical resilience and ability to rebound from downturns. This elevated valuation suggests investors expect steady profit growth despite competitive pressures and rapid tech sector changes. With high margins and recurring revenue, Apple's Services division (App Store, Apple Music, iCloud, and more) is now the company's growth engine. iPhone demand, especially in China and India, remains a central driver, with an anticipated surge for the iPhone 17 launch in the third quarter of 2025. AI has been called an 'elephant in the room.' Apple's monetization strategy there has yet to emerge, with Wall Street still waiting for significant generative AI products. Competitive and regulatory headwinds are increasing, but Apple's pricing power and sticky ecosystem underpin optimism for the long-term. Don't Miss: The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — and you can too at just $2.90/share. Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Here's how you can earn passive income with just $100. Wall Street sentiment toward Apple (AAPL) is broadly positive. According to Benzinga, 29 analysts cover the stock, with a consensus price target of $233.04, ranging from a high of $300 (Tigress Financial) to a low of $160 (HSBC). The three most recent ratings from Wedbush, B of A Securities, and DA Davidson average $256.67, implying about 12.7% upside from current levels. This reflects optimism about Apple's long-term growth despite ongoing debates over its innovation pace and competitive pressures. Quick Snapshot Table of PredictionsYear Lowest Prediction Average Prediction Maximum Prediction 2025 $170 $225 $300 2026 $218 $362 $411 2027 $245 $362 $420 2028 $290 $387 $470 2029 $320 $412 $495 2030 $287 $349 $410 The forecast range in this table is based on algorithmic projections provided by Coin Price Forecast, StockScan, CoinCodex, and Market Beat. These models use historical price trends, volatility patterns, and moving averages to estimate future stock prices over multiple time horizons. Bull & Bear Case Before making a decision on Apple stock, it's crucial to weigh both the optimistic arguments for continued growth and the potential headwinds that could limit future returns. Bull Case Growth from iPhone replacement cycle (iPhone 17 and beyond), surging Services segment, and potential upside from new AI features or augmented reality/virtual reality (AR/VR) launches. High-margin services and wearables provide recurring revenue and ecosystem lock-in. Most analysts maintain "Buy" or "Moderate Buy" ratings for AAPL, citing balance sheet strength, buybacks, and innovation pipeline. Bear Case Regulatory and antitrust scrutiny in the U.S. and Europe could limit the percentage Apple collects from App Store sales or hamper new services. Margins pressured as hardware growth slows, especially given Chinese competition/risk of supply chain disruptions. Apple's current valuation remains rich unless earnings growth accelerates; any disappointment could prompt a sharp downside given macro risks. Despite Apple's massive resources, the company faces persistent criticism for lagging behind peers like Microsoft, Google, and even Meta in the rollout of advanced generative AI features. Apple Stock Price Prediction for 2025 Forecast Range: $170–$300 Analysts see moderate upside from today's price of around $224, with bulls eyeing further gains into late 2025 should the iPhone cycle and services outpace current estimates. A key risk is that valuation multiples could compress if revenue trends don't reaccelerate. Competitive gains from rivals and global regulation remain overhangs. Apple Stock Price Prediction for 2026 Forecast Range: $218–$411 2026 targets diverge, with some models projecting steady, earnings-driven creep, while others foresee strong upside from new platform adoption (AI, wearables). Bullish scenarios anticipate 60% to 80% upside if innovation cycles hit. Apple Stock Price Prediction for 2030 Forecast Range: $287–$478 A balanced CAGR model (8% to 12% annualized) from today suggests AAPL could close 2030 between $350 and $415. Structural upside exists if new categories (AR glasses) scale successfully. Downside risks are disruption to Apple's ecosystem, regulatory interventions, or margin erosion as competition heats up. Investment Considerations Apple remains a core blue chip, suitable for long-term growth investors, tech believers, and dividend reinvestors. Its record of buybacks, dividend hikes, and world-class brand equity keeps institutional and retail holders committed. As of mid-2025, hedge funds and pensions maintain overweight exposure, betting on Apple's proven playbook of ecosystem expansion and cash generation. Key risks: macroeconomic swings, intensified tech competition (especially in China), global regulatory action, and elevated earnings multiple. Upcoming catalysts to watch include Q3 earnings (iPhone 17 launch), Services segment margin growth, and the debut of new AI-powered features. Diversified investors should monitor Apple's valuation multiples and sector positioning. Significant drawdowns are possible if revenue growth disappoints or global tech sentiment sours. See Next: 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share. This article AAPL Stock Price Prediction: Where Apple Could Be by 2025, 2026, and 2030 originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
2 Great Dividend Stocks for the Long Haul You'll Likely Wish You Bought 10 Years From Now
Key Points Tractor Supply delivers a modest but well-supported dividend backed by a resilient rural retail niche. Starbucks offers a higher yield, but its payout ratio exceeds earnings, leaving investors dependent on management's business turnaround plan. Both dividend stocks look attractive for their own unique reasons. These 10 stocks could mint the next wave of millionaires › Tractor Supply (NASDAQ: TSCO) and Starbucks (NASDAQ: SBUX) have both established themselves as dependable dividend payers. Yet, their strengths, risks, and income profiles could not be more different. Tractor Supply, the leading rural retailer, has a smaller yield but comes with a track record of measured growth and strong coverage. Coffee giant Starbucks offers a richer payout but faces questions about its sustainability. Let's take a look at how each company's dividend stacks up today, consider the underlying business trends that support (or challenge) those payouts, and explore what income-focused investors should keep in mind before committing capital for the long haul. Choosing whether to invest in either of these companies isn't just about their dividend yield today. It's more complex than that. So, let's dig into what makes each of these dividend stocks unique and attractive in their own right. Tractor Supply: steady fundamentals and a sustainable payout Based on its stock price today, Tractor Supply offers investors a dividend yield of about 1.5%, paying $0.92 annually (the quarterly payment currently stands at $0.23). Importantly, the company has a payout ratio of just 44%, leaving plenty of room for the company to pay shareholders quarterly while reinvesting in its operations and repurchasing shares. In addition, a low payout ratio like this enables the rural retailer to maintain these practices while continuing to raise its dividend over time. Indeed, with 16 consecutive years of dividend increases, Tractor Supply has demonstrated a commitment to rewarding shareholders with a growing stream of cash in a disciplined fashion. Another key factor making Tractor Supply look attractive is its loyalty program, Neighbor's Club. The program now has 41 million members. Highlighting its importance, 80% of its sales come from members. This program drives repeat visits and helps the company better target promotions. It's a quiet advantage that supports the company's growth story and ultimately its dividend growth prospects. Tractor Supply's business has been resilient, benefiting from steady demand in rural and suburban markets. Its focus on rural lifestyle products, store expansion, and customer loyalty programs has provided a reliable growth engine. Starbucks: higher yield but more risk Starbucks pays a dividend yield of roughly 2.6% as of this writing. Its quarterly payments total $2.44 annually. While the payout is more generous than Tractor Supply's, there's more risk to it. This is evidenced by the fact that the company's payout ratio currently exceeds 100% of earnings. That means the coffee giant is currently paying more in dividends than it earns, raising questions about the dividend's long-term sustainability at this level unless profits improve. At the moment, the business doesn't look great on the surface. In its most recent quarter, Starbucks reported generally accepted accounting principles (GAAP) earnings per share of $0.49, compared with a quarterly dividend of $0.61. Management has also notably opted not to provide full-year 2025 guidance as it works through plans to revitalize its business. So, for now, we just have to hope the company's slow revenue growth (sales increased just 2% year over year in the company's most recent quarter) will pick back up soon. Despite rough fundamentals at the moment, management is confident about the company's future. It believes its current negative sales trends are only temporary. Under new leadership, Starbucks is working to simplify its menu, speed up service, and modernize operations. If these efforts are successful and uncertainty is replaced by excitement, the stock price could benefit and the dividend will likely get robust support from growing earnings. For now, however, the higher yield comes with greater uncertainty. But that doesn't mean investors should rule Starbucks out. The higher yield helps make up for some of the uncertainty. Additionally, the stock price could jump if the company starts demonstrating a successful turnaround. The verdict on both of these dividend stocks? They make a dynamic pair when bought together. For investors seeking a reliable, lower-risk income stream backed by a durable business model, Tractor Supply is a great dividend investment idea. Its modest dividend yield is backed by a durable business, a long history, and excellent financials. Starbucks, on the other hand, offers a higher yield and the potential for a jump in the stock price if management's efforts to revitalize the business are successful. Should you buy stock in Starbucks right now? The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Daniel Sparks and his clients have no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Starbucks and Tractor Supply. The Motley Fool recommends the following options: short October 2025 $60 calls on Tractor Supply. The Motley Fool has a disclosure policy. 2 Great Dividend Stocks for the Long Haul You'll Likely Wish You Bought 10 Years From Now was originally published by The Motley Fool
